Literature DB >> 27490037

Design of Novel Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors: Virtual Screening, Synthesis and In Vitro Biological Activities.

Parthiban Brindha Devi1, Sridhar Jogula1, Asireddy Parameshwar Reddy1, Shalini Saxena1, Jonnalagadda Padma Sridevi1, Dharmarajan Sriram1, Perumal Yogeeswari2.   

Abstract

Pantothenate synthetase (PS) enzyme involved in the pantothenate biosynthetic pathway is essential for the virulence and persistent growth of Mycobacterium tuberculosis (MTB). It is encoded by the panC gene, and has become an appropriate target for developing new therapeutics for tuberculosis. Here we report new inhibitors active against MTB PS developed using energy based pharmacophore modelling of the available proteininhibitor complex (3IVX) and virtual screening of a large commercial library. The e-pharmacophore model consisted of a ring aromatic (R), negative ionizable (N) and acceptor (A) sites. Compounds 5 and 10 emerged as promising hits with IC50 s 2.18 µM and 6.63 µM respectively. Further structural optimization was attempted to optimize lead 10 using medicinal chemistry approach and six compounds were found to exhibit better enzyme inhibition compared to parent compound lead 10 (<6 µM).
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Enzyme ïnhibition; Hit optimisation; Pantothenate synthetase; Tuberculosis; Virtual screening; e-Pharmacophore

Mesh:

Substances:

Year:  2015        PMID: 27490037     DOI: 10.1002/minf.201400120

Source DB:  PubMed          Journal:  Mol Inform        ISSN: 1868-1743            Impact factor:   3.353


  1 in total

Review 1.  Inhibitors of pantothenate synthetase of Mycobacterium tuberculosis - a medicinal chemist perspective.

Authors:  Amaroju Suresh; Singireddi Srinivasarao; Yogesh Mahadu Khetmalis; Shashidhar Nizalapur; Murugesan Sankaranarayanan; Kondapalli Venkata Gowri Chandra Sekhar
Journal:  RSC Adv       Date:  2020-10-07       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.